2023
AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles
Li H, Seifer D, Tal R. AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles. Reproductive Biology And Endocrinology 2023, 21: 19. PMID: 36739415, PMCID: PMC9898926, DOI: 10.1186/s12958-023-01066-w.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormoneNumber of embryosEuploid embryosLive birthsOocyte qualityAge groupsSignificant independent predictorsCase-control analysisSART CORS databasePreimplantation genetic testingAMH levelsIVF cyclesIndependent predictorsIVF outcomesOocyte yieldNormal embryosPredictive roleGenetic testingFinal analysisBirthAgeIVFSubset of cyclesHormonePGT
2009
Trends of racial disparities in assisted reproductive technology outcomes in black women compared with white women: Society for Assisted Reproductive Technology 1999 and 2000 vs. 2004–2006
Seifer DB, Zackula R, Grainger DA, Report S. Trends of racial disparities in assisted reproductive technology outcomes in black women compared with white women: Society for Assisted Reproductive Technology 1999 and 2000 vs. 2004–2006. Fertility And Sterility 2009, 93: 626-635. PMID: 19368916, DOI: 10.1016/j.fertnstert.2009.02.084.Peer-Reviewed Original ResearchConceptsWhite womenCycles of IVFPoor prognostic factorReproductive technology outcomesNon-Hispanic womenBlack womenTubal factorIVF cyclesOvulation disordersCohort studyOvarian reserveIVF outcomesPrognostic factorsUterine factorsReporting of raceMale factorLive birthsMAIN OUTCOMEART outcomesMember clinicsOlder ageRacial disparitiesWomenFresh embryosReproductive technologies
2005
Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology
Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, Keefe DL, Blazar AS. Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Human Reproduction 2005, 21: 159-163. PMID: 16123085, DOI: 10.1093/humrep/dei270.Peer-Reviewed Original ResearchConceptsBasal FSH levelsOvarian reserveFSH levelsHCG administrationMIS levelsIVF outcomesOocyte qualityDay 3 FSH levelsMI levelsImproved oocyte qualityTime of hCGClinical pregnancy rateManagement of patientsSerum estradiol levelsHigher implantation rateEmbryo morphologyEmbryo morphology scoreNumber of oocytesEarly antral folliclesEnzyme-linked immunosorbentIVF cyclesOocyte retrievalPatient ageEstradiol levelsImplantation rate
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction